ARIX.L Share News (ARIX)

IN BRIEF: Arix Bioscience shares suspended ahead of RTW takeover

Arix Bioscience PLC - London-based venture capital firm focused on biotechnology companies - Shares suspended from the London Stock Exchange amid the company's acquisition by RTW Biotech Opportunities Ltd, a New York-based investment firm focused on the life sciences sector.

UK shareholder meetings calendar - next 7 days

IN BRIEF: RTW Biotech completes Arix investment in takeover run-up

RTW Biotech Opportunities Ltd - New York-based investment firm focused on the life sciences sector - Says it completed on Friday its previously announced acquisition of a 25.5% stake in Arix Bioscience PLC for USD57.1 million, equivalent to GBP1.37 per Arix share. Purchase is to support its planned all-share acquisition of Arix's assets. Arix says RTW on January 15 received confirmation from the UK Financial Conduct Authority that it has approved the proposed change of control. Companies say that as planned, Non-Executive Directors Maureen O'Connell and Isaac Kohlberg have resigned from Arix's board, effective Friday.

IN BRIEF: Arix Bioscience eyes USD19 million return from Harpoon sale

Arix Bioscience PLC - London-based venture capital firm investing in "breakthrough" biotechnology companies - Expects USD18.6 million net proceeds from its USD680 million sale of Harpoon Therapeutics, a clinical-stage immunotherapy company, to Rahway, New Jersey-based pharmaceutical maker Merck & Co Inc. Anticipates transaction to close in the first half of 2024. Arix Chair Peregrine Moncreiffe says: "Arix has been an investor in Harpoon Therapeutics since 2017, and it is great to see a company that we have been a part of since the early stages move through the clinic and receive recognition for the platform they have worked hard to develop. This acquisition by Merck provides significant potential for bringing life-saving treatment to cancer patients as they enhance their oncology pipeline. In what has been a difficult time across the biotech sector we see this M&A activity as a further sign of market recovery."

RTW Biotech agrees "immediately accretive" Arix Bioscience takeover

(Alliance News) - RTW Biotech Opportunities Ltd on Wednesday said it has agreed to acquire all the assets of fellow London listing Arix Bioscience PLC in exchange for new RTW shares, and to buy a 25.5% stake from Arix's largest shareholder in cash.

TRADING UPDATES: Gran Tierra completes offers, Pensana wins grant

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Monday and Tuesday and not separately reported by Alliance News:

Arix Bioscience boosts net value, CEO jumping ship for PureTech Health

(Alliance News) - Arix Bioscience PLC on Wednesday said net asset value increased in its latest half year, but has since launched a strategic review due to "unfavourable" conditions while Chief Executive Officer Robert Lyne prepares to step down.

UK earnings, trading statements calendar - next 7 days

IN BRIEF: Arix Bioscience reports dip in portfolio value in July

Arix Bioscience PLC - venture capital company focused on investing in breakthrough biotechnology companies - Reports a net asset value per share of GBP1.84 as at July 31, down from GBP1.86 as at June 30. Listed portfolio value falls to GBP69 million as at July 31 from GBP71.2 million as at June 30.

UK earnings, trading statements calendar - next 7 days

Arix Bioscience launches strategic review despite value increase

(Alliance News) - Arix Bioscience PLC on Thursday announced its net asset value had increased, but that it plans to launch a strategic review concerning issues like its discounted share price.

IN BRIEF: Arix Bio portfolio company Disc raises USD157.8 million

Arix Bioscience PLC - London-headquartered venture capital company focused on biotechnology companies - Says its portfolio company Disc Medicine has raised USD157.8 million via a placing of 3.0 million new shares and pre-funded warrants to purchase 204,081 shares. Says the shares were sold at USD49.00 per share. Says Disc will use the funds for the research and clinical development of its current or additional product candidates, as well as for working capital. Notes that Arix's holding in Disc has reduced from 3.1% to 2.7% following the placing.

UK shareholder meetings calendar - next 7 days

IN BRIEF: Arix reports NAV per share of 177 pence at end of April

Arix Bioscience PLC - London-based transatlantic venture capital company focused on investing in biotechnology companies that are advancing in life science - Reports its estimated net asset value stood at 177.0 pence per share at April 30.

DIRECTOR DEALINGS: Ferro-Alloy Resources CEO lifts stake to 13%

(Alliance News) - The following is a round-up of share dealings by London-listed company directors and managers announced this week and not separately reported by Alliance News: